About: Abituzumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.

Property Value
dbo:abstract
  • Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. (en)
dbo:casNumber
  • 1105038-73-0
dbo:fdaUniiCode
  • 724QD330RD
dbo:wikiPageID
  • 49481717 (xsd:integer)
dbo:wikiPageLength
  • 9377 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 996024336 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:casNumber
  • 1105038 (xsd:integer)
dbp:chemspiderid
  • none (en)
dbp:mabType
  • mab (en)
dbp:source
  • zu (en)
dbp:target
dbp:type
  • mab (en)
dbp:unii
  • 724 (xsd:integer)
dbp:wikiPageUsesTemplate
dct:subject
gold:hypernym
rdf:type
rdfs:comment
  • Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. (en)
rdfs:label
  • Abituzumab (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License